Core Insights - The core product of the innovative drug company, Cloudtop New Medicine Technology Co., Ltd. (云顶新耀), NEFECON® (Budesonide Enteric Capsules), has been included in the 2025 KDIGO Clinical Practice Guidelines for IgA Nephropathy and IgA Vasculitis, becoming the only recommended causal treatment for IgA nephropathy in the guidelines [1] Group 1 - IgA nephropathy is characterized by the deposition of Immunoglobulin A (IgA) immune complexes in the glomeruli, leading to kidney inflammation and potential progression to chronic kidney failure. In China, there are approximately 5 million IgA nephropathy patients, with over 120,000 new cases diagnosed each year [1] - The guidelines emphasize "early intervention, precise treatment, and improved prognosis" as core objectives, achieving multidimensional breakthroughs in the entire process of IgA nephropathy diagnosis and treatment, which is considered a milestone for global clinical practice [1] - The guidelines highlight the need to manage specific driving factors of nephron loss and stress the importance of intervening at the source to reduce immune damage to the kidneys [1] Group 2 - The inclusion of NEFECON® in the 2025 KDIGO guidelines not only provides new treatment options for IgA nephropathy patients but also signifies a shift in global treatment strategies. Previously, due to a lack of effective causal treatment, nearly all patients faced the risk of kidney function decline to end-stage renal disease [1] - The new guidelines advocate for early diagnosis and treatment, focusing on immunological interventions to reduce kidney immune damage, thereby changing the treatment pathway and promoting causal treatment as the mainstream approach [1]
云顶新耀耐赋康®获2025 KDIGO指南推荐 成为唯一推荐的IgA肾病对因治疗药物